Some studies indicate that immune cells and CAFs secrete IL-6 to activate JAK/STAT3 and PI3K/AKT signaling pathways in tumor cells, which results in the degradation of ERα through the ubiquitin protease pathway, leading to tamoxifen resistance in breast cancer (45). This evidence concerns the gene AKT1 and neoplasm.